1. Introduction
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy with overall survival rate of 80–90%. One of contributors for this high survival rate is the maintenance therapy with 6-mercaptopurine (6-MP) [1].
Mercaptopurine, one of thiopurine drugs, is commonly used as a maintenance regimen for childhood ALL and has played an important role in long-term remission. However, 6-MP has a narrow therapeutic index. It then causes dose-limiting toxicities in hematopoietic tissues, resulting in neutropenia or febrile neutropenia. Because these toxicities negatively affect ALL treatment outcomes, there have been attempts to find the risk factors causing these toxicities especially in the pharmacogenetics area [2,3].
Mercaptopurine is converted to the main therapeutic metabolites 6-thioguanine nucleotides (TGNs), comprising thioguanosine-5′-triphosphate (TGTP), thioguanosine-5′-diphosphate (TGDP), and thioguanosine-5′-monophosphate (TGMP) by multi-enzymatic steps [4]. TGNs have wide spectrum immunosuppressive roles by incorporation into RNA or DNA and inhibit DNA synthesis [5,6]. Thiopurine S-methyltransferase (TPMT) is the principal enzyme in the regulation of thiopurine metabolism by metabolizing TGNs to inactive, nontoxic compounds. Patients with a nonfunctional variant allele of TPMT have lower TPMT enzyme activity, and consequently 6-TGN excessively accumulates in hematopoietic tissues and frequently causes hematopoietic toxicity [7,8,9]. These findings lead to the concept of individualized 6-MP dosing according to TPMT genotype. However, TPMT alone cannot account for the individual-specific differences in 6-MP sensitivity [3], and the frequency of the variant TPMT alleles differs between ethnic groups [10]. Although approximately 10% of the Caucasian population carries a nonfunctional sequence variant, its frequency is exceptionally low in Asian populations, which brought limits to the application of the TPMT genotype to regulating dose of 6-MP in Asian ALL patients [11].
Recently, several other genes related to thiopurine toxicity have been reported. Nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) is a nucleotide diphosphatase that can convert TGTP to TGMP and is thus responsible for the inactivation of thiopurine metabolites [12]. A nonsynonymous rs116855232 NUDT15 variant (c.415C>T, p.Arg139Cys) has been reported as a strong risk factor for thiopurine-induced leukopenia and 6-MP intolerance in patients with inflammatory bowel disease and pediatric ALL in several reports [12,13,14,15,16,17]. As the frequency of this SNP is ~6–10% of the East Asian population, NUDT15 has been suggested as a useful alternative marker for TPMT variants in East Asians [18]. Other SNPs in NUDT15 such as p.Arg139His, p.Val18Ile, p.Val18_Val19insGlyVal, p.Arg34Thr, p.Lys35-Glu, p.Gly17_Val18del, p.Met1Thr, and p.Gly47Arg have also been uncovered and are undergoing evaluation [12,13,14,15,16,17].
Inosine triphosphate pyrophosphatase (ITPA) is another enzyme involved in 6-MP metabolism. ITPA catalyzes the hydrolysis of inosine triphosphate (ITP) to inosine monophosphate (IMP), protecting cells from the accumulation of harmful nucleotides such as ITP and deoxyinosine triphosphate [19]. The most well established deleterious ITPA variants associated with 6-MP-related toxicity are rs1127354 (c.94C>A) and rs7270101 (IVS2+21A>C) [20]. ITPA enzyme deficiency arising from genetic variants affects 5–7% of Caucasians and Africans, and up to 15% of Asians [21]. Despite the high frequency of these variation, their clinical relevance in the predictive role for 6-MP toxicities is still controversial.
Apurinic/apyrimidinic endonuclease 1 (APEX1) is another gene candidate reported recently. The missense variation rs2307486 (c.190A>G) in APEX1 is strongly related to early onset MP-related neutropenia in pediatric ALL patients [22]. Although human APEX1 is the major enzyme in the DNA base excision repair pathway, and APEX1-deficient cells have been shown to exhibit sensitivity to antimetabolites in an in vivo study [23], its clinical relevance in 6-MP treatment has yet not been evaluated much.
The aim of this study is to identify the frequencies of major polymorphisms of candidate genes, TPMT, NUDT15, ITPA, and APEX1, and evaluate whether these variations and combination of them could predict 6-MP intolerance and toxicity during maintenance therapy in pediatric ALL patients.
2. Materials and Methods
2.1. Patients and Data Collection
This study was conducted according to the tenets of the Declaration of Helsinki with the approval of the institutional ethics committee (IRB No. 2019-11-074 Keimyung University Dongsan Hoispital, 2019-12-0072 Yeungnam Uni-versity Hospital). A total of 83 pediatric ALL patients were analyzed, including 56 males and 27 females. The median age at diagnosis was 8.3 years (range: 1.0–16.2 years). There were 52 patients who were allocated to the standard-risk group, 25 to the high-risk group, and six were in the very high-risk group, in accordance with National Cancer Institute (NCI) risk group classification [24,25]. The median follow-up duration was 9.1 years (range: 0.9–16.6 years) (Table 1).
Maintenance chemotherapy consisted of oral prednisolone (40 mg/m2) for five days and intravenous vincristine (1.5 mg/m2) every four weeks, daily oral 6-MP (75 mg/m2), weekly oral methotrexate (MTX) (15 mg/m2), and intrathecal chemotherapy (MTX alone or triple regimen [MTX, cytarabine, and hydrocortisone]) every 12 weeks. The doses of 6-MP and MTX were adjusted according to the complete blood count (CBC) and liver function tests (LFT) by a blood test every two weeks. During the maintenance chemotherapy, the target WBC values were 1.5–3.5 × 103/mm3 with ANC < 1.5–2.0 × 103/mm3 [26,27]. The medications were interrupted if the patients developed a grade three or greater hepatic toxicity, based on the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE 5.0); if aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5.0–20.0 × upper limits of normal (ULN), or for a blood bilirubin > 3.0–10.0 × ULN. The medications were also stopped in cases of grade three or greater hematologic toxicities (ANC < 1.0–0.5 × 103/mm3) with a febrile infectious event occurring during maintenance chemotherapy.
Neutropenia is defined as a neutrophil count of 0.5 × 103/mm3 or less. For early neutropenia, ANC at 14th day and 28th day were analyzed. Febrile neutropenia is defined as two or more temperature spikes of 38.0 °C or greater at least 1 hour apart, or as a single spike of 38.3 °C or greater, along with a neutrophil count of 0.5 × 103/mm3 or less at the time of the fever or a decrease to 0.5 × 103/mm3 or less within 48 h of fever onset. Numbers of neutropenia and febrile neutropenia episodes during maintenance therapy were retrospectively collected using patient medical records.
Data of a 6-MP dose and a 6-MP dose intensity (%) was collected on the 13th (2nd maintenance period), and the 61st (6th maintenance period) week during maintenance chemotherapy, as well as at the final maintenance period. The 6-MP dose intensity (%) was calculated as the ratio of the actual prescribed 6-MP dose by physician and the protocol dose. Hepatotoxicity was defined as an ALT or AST level > 200 U/L at any time point during maintenance therapy.
2.2. Genotyping
Genotyping for the following polymorphisms from five genes was performed: NUDT15 c.415C>T (rs116855232), NUDT15 c.55_56insGAGTCG (rs746071566), ITPA c.94C>A (rs1127354), ITPA c.IVS2+21A>C (rs7270101), APEX1 c.190A>G (rs2307486), TPMT*2 c.238G>C (rs1800462), TPMT*3B c.460G>A (rs1800460), TPMT*3C c.719A>G (rs1142345), TPMT*4 c.626-1G>A (rs1800584), and TPMT*3A being the combination of the TPMT*3B and TPMT*3C genotypes.
Genomic DNA was isolated from 150 μL peripheral blood using the QIAamp DNA blood Mini kit from Qiagen (Germantown, MD, USA) and stored at −20 °C until analysis. Amplification was performed using Smart Tag Premix (Solgent Co., Daejeon, Korea). Briefly, 200 ng of DNA template and 1 μL each of forward and reverse primers were added to the PCR premix (20 μL final volume). Sanger sequencing was performed using the following primers: NUDT15 c.415C>T, forward 5′-CAAGCAAATGCAAAGCATCA reverse 5′-GGCTGAAAGAGTGGGGGATA; NUDT15 c.55_56insGAGTCG, forward 5′-GCGCTCTCGCTTTGATTTC reverse 5′-GAACGCGCAAGAAAGGAC; ITPA c.94C>A and IVS2+21A>C, forward 5′-TAGGAGATGGGCAGCAGAGT reverse 5′-CCTGGAAGCTACCTGGACAA; APEX1 c.190A>G, forward 5′-CAGTTGGAAACCACCAGCTT reverse 5-CAGAAAACTACGGGCAGGAG; TPMT c.238G>C, forward 5′-TCCTGCATGTTCTTTGAAACC reverse 5′-TCGGTGATTGGTTCTTCTGA; TPMT c.460G>A, forward 5′-GGGACGCTGCTCATCTTCT reverse 3′-TTCAAACTCATAGAAGTCTAAGCTGAT; TPMT c.719A>G and c.626-1G>A, forward 5′-GAATCCCTGATGTCATTCTTCA reverse 5′-CATTACATTTTCAGGCTTTAGCA.
Amplification parameters were an initial denaturation step of 95 °C for 30 s, annealing at 60 °C for 30 s, and extension at 72 °C for 45 s for all reactions. The quality and sizes of PCR products were assessed by electrophoresis in a 1.5% agarose gel. Products were purified and bidirectionally sequenced using a BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA) on an ABI 3500xl DNA analyzer (Applied Biosystems, 850 Lincoln Centre Drive, Foster City, CA, USA). Mutations were identified using the Sequencher software (version 5.4.5).
2.3. Statistical Analysis
Data was entered and analyzed in SPSS v.26 (IBM Corporation, Armonk, NY, USA). Correlations between the index of 6-MP-related toxicities (absolute neutrophil count [ANC], days of ANC < 1 × 103/mm3, days of ANC < 0.5 × 103/mm3, frequency of febrile neutropenia, maximum AST and ALT), 6-MP intolerance (6-MP dose and 6-MP dose intensity at second, sixth and final maintenance therapy periods), and genetic variations were analyzed using Mann–Whitney U test. A p-value of less than 0.05 was considered statistically significant.
3. Results
3.1. Patient Characteristics, Genotype Data, and Allele Frequencies
Most of the enrolled children experienced episodes of neutropenia during the entire period of maintenance therapy. Seventy-six (91.6%) children experienced <1 × 103/mm3 neutropenia during at least one day (268.3 ± 224.8 days), and 70 (84.3%) children experienced <0.5 × 103/mm3 neutropenia during 136.8 ± 132.0 days. Sixty-one (73.5%) children experienced febrile neutropenia during 6.1 ± 5.3 days. An ANC at the 14th day and 28th day from initiation of maintenance therapy was 708.8 ± 824.1/mm3, and 188.6 ± 383.4/mm3, respectively. The 6-MP dose was started at 75 mg/m2 for all patients and an adjusted dose at the second, sixth, and final maintenance therapy cycles were 51.6 ± 19.1 mg/m2, 48.5 ± 16.5 mg/m2, and 45.3 ± 15.3 mg/m2, respectively. The 6-MP dose intensities were 70.0 ± 24.8%, 66.3 ± 22.5%, and 61.7 ± 21.0%, respectively. The maximum AST, ALT levels during maintenance therapy were 303.9 ± 220.7 IU/L and 636.3 ± 458.6 IU/L, respectively (Table 1). The differences of these indices according to age group (<10, ≥10 years), risk group (intermediate, high, and very high groups), and sex were not found (data not shown).
Genotype frequencies for NUDT15 c.415C>T, NUDT15 c.55_56insGAGTCG, ITPA c.94C>A, ITPA c.IVS2+21A>C, APEX1 c.190A>G, and TPMT are summarized in Table 1. Of the 83 children tested, 46 (55.4%) carried at least one of the sequence variants of them: NUDT15 c.415C>T, 16 (19.3%); NUDT15 c.55_56insGAGTCG, 9 (10.8%); ITPA c.94C>A, 21 (25.3%); ITPA c.IVS2+21A>C, 1 (1.2%); APEX1 c.190A>G, 9 (10.8%); TPMT variant 1*/3*, 1 (1.2%). Eight of the NUDT15 c.55_56insGAGTCG carriers were accompanied by c.415C>T as diplotype *1/*2, and only one patient carried the sole c.55_56insGAGTCG as diplotype *1/*6 [18]. Nine patients carried more than 2 variants and combinations of them are listed in Table 1. Because of low allele frequency or co-occurrence with c.415C>T, the variant of TPMT, ITPA IVS2+21A>C and NUDT15 c.55_56insGAGTCG were excluded in the analysis as an independent pharmacogenetic markers.
3.2. Associations between Genetic Polymorphisms and 6-Mercaptopurine Related Toxicities and Intolerances
When the entire maintenance treatment period had been considered, there was no statistically significant associations between the investigated sequence variants and neutropenia (those experienced on days of <5 × 103 and <1 × 103 /mm3 neutropenia, days of febrile neutropenia, ANC at 14th and 28th day) (Table 2). The NUDT15 c.415C>T carriers were likely to have a lower ANC on the 28th day than the wild type, but this was not statistically significant (Table 2). When considering the 6-MP doses at second, sixth, and final maintenance therapy sessions, the NUDT15 c.415C>T allele carrier showed significantly low 6-MP doses at final maintenance therapies than the wild type carrier (p = 0.007 respectively) (Figure 1). The 6-MP dose intensities at the sixth and final maintenance period were also significantly low in NUDT15 c.415C>T carriers (p = 0.003 and 0.008, respectively) (Figure 2). Maximum AST, and ALT levels were not associated with variants. Because of the low number of patients carrying more than two variants, their synergic effect could not be analyzed except for the NUDT15 c.415C>T and ITPA c.94C>A. When analyzing the effect of the coexistence of NUDT15 c.415C>T and ITPA c.94C>A, no 6-MP toxicity differences were found between the NUDT15 c.415C>T carrier and carrier with both variations (Table S1).
4. Discussion
In this study, the authors investigated the effects of major polymorphisms of four genes, NUDT15, ITPA, APEX1, TPMT on 6-MP-related toxicities or intolerance. Authors found that NUDT15 c.415C>T had a lowering effect on 6-MP dose during maintenance therapy in pediatric ALL patients.
As reported in previous studies, the TPMT and ITPA c.IVS2+21A>C variants were extremely low in our study population [12,28]. Thus, ITPA c.IVS2+21A>C and TPMT variants were inappropriate for use as a pharmacogenetic marker for thiopurine therapy in Korean ALL patients. The frequencies of ITPA c.94C>A and APEX1 c.190A>G were 25.3% and 10.8%, respectively. This is similar with previous studies reporting 21.9–27.0% [28,29], and 14.1% for Korean population [22].
The NUDT15 c.415C>T variant was reported to be a major predictive marker for thiopurine-related myelosuppression, particularly in Asian and Hispanic people. Yang et al. identified NUDT15 c.415C>T as being strongly associated with thiopurine-induced early leukopenia in Crohn’s disease [12]. Tanaka et al. found that leucopenia is more common in NUDT15 c.415C>T carriers in pediatric ALL patient, and leucopenia results in a significant 6-MP dose reduction [30]. In our study, we collected information about neutropenia, such as the days with <5 × 103 and <1 × 103/mm3 neutropenia, days with febrile neutropenia, and we took an ANC on day 14 and 28 of maintenance therapy as early neutropenia index. But we found no significant relationship between genotypes and early neutropenia, neutropenic duration, and febrile neutropenia. However, the doses of 6-MP and dose intensity at the sixth, and final maintenance therapy sessions were significantly low in NUDT15 c.415C>T carriers. The clinicians regulated the 6-MP doses according to the patients’ neutrophil count, fever event, hepatotoxicity, or patient health status. Therefore, the adjustment of the 6-MP dose could be an indicator for 6-MP intolerance. Yi et al. reported a low 6-MP dose and longer duration of therapy interruption in NUDT15 c.415C>T carriers [31]. Moreover, Yang et al. found NUDT15 c.415C>T homozygote carriers were exquisitely sensitive to MP, with a significantly low average dose intensity of 8% in child ALL patients [13]. In addition to NUDT15 c.415C>T, other variants such as p.Arg139His, p.Val18Ile, p.Val18_Val19insGlyVal, p.Arg34Thr, p.Lys35-Glu, p.Gly17_Val18del, p.Met1Thr, and p.Gly47Arg have also been uncovered. Except for p.Val18_Val19insGlyVal (c.55_56insGAGTCG), other variants are present very infrequently, but these variants also showed the effect of a 74.4–100% loss of nucleotide diphosphatase activity resulting in excessive levels of thiopurine active metabolites and toxicity [16,32]. In particular, the p.G17_V18del variant protein showed extremely low thermostability and was completely void of catalytic activity, thus likely to confer a high risk of thiopurine intolerance [32]. To find out the mechanism of this NUDT15 variant, a few in vivo studies were conducted. In a recent study of the knock-in mouse model, the NUDT15-/- mice experienced severe leukopenia, rapid weight loss, early death, and more bone marrow hypocellularity on 6-MP therapy as compared to the wild type mice [33]. In another study, a clinically relevant dose of MP induced lethal cytopenia in NUDT15 c.415C>T harboring mice not only in the homozygote variant but also in the heterozygote variant. Even lower-dose MP during long-term administration caused stronger damage than wild type [34]. These in vivo studies support the preemptive NUDT15 genotype–guided thiopurine dosing to prevent toxicity.
Before NUDT15, a variant of ITPA was represented as a potential marker of 6-MP sensitivity, especially in populations with a low frequency of the TPMT variant. But the clinical relevance of ITPA genotyping in 6-MP toxicity prediction is still controversial [35,36,37]. In our study, although the frequency of ITPA c.94C>A was sufficiently high, we could not discover a significant relationship with neutropenia or 6-MP dosing. A total of five patients carried both the ITPA c.94C>A and NUDT15 c.415C>T variants. We then compared those patients having only NUDT15 variant with those who had both the NUDT15 and ITPA variants to analyze their synergistic effects. Although those with both variations were likely to have the lower ANC on the 14th day, we could not find any statistically significant differences of neutropenia or 6-MP dose between either the NUDT15 carriers or both carriers (Supplementary Table S1). To analyze the synergistic effects of additional other variants, a study of a larger populations is needed.
APEX1 c.190A>G has relatively recently been proposed as a candidate gene, which has been revealed to have a strong relation with early onset MP-related neutropenia occurring within 28 days as well as a cumulative incidence of MP-related neutropenia [22]. Human APEX1 is the major enzyme in the DNA base excision repair pathway where its main role is to create a nick in the phosphodiester backbone [23]. The allele frequencies of the variant alleles in c.190A>G were near 0% in Europeans, 0.08% in Africans, and 1.73% in Americans, whereas they were 4.66% in East Asian individuals, according to the 1000 Genomes database [22]. In the previous study of McNeill et al., APEX1-deficient cells were shown to exhibit the greatest sensitivity to antimetabolites among various anticancer drugs, and consequently apoptotic cell death was profoundly increased, supporting a role for mutant APEX1 in thiopurine-induced neutropenia [23]. In our study, although the patient number is small, the frequency of variants was relatively high, 10.8%, and all of them were heterozygote. Although a meaningful effect on 6-MP toxicities was not found in this study, a larger-scale study is needed for a new candidate gene.
The low incidence of the TPMT variant in Asian population has brought a discovery of new pharmacogenetic markers predicting 6-MP toxicities, such as NUDT15, ITPA, and APEX1. As new markers have been uncovered, identification of clinical significance and the synergic effect of those markers has been important. In this study, we could not find a distinct predictive role for these variations and their synergistic effect on myelosuppression such as neutropenia, but carriers with NUDT15 c.415C>T showed lowered 6-MP dose meaning 6-MP intolerance. This limited result might be due to the relatively low numbers of patients or retrospective study design. The sample size of the study is small for assessment of multiple genetic variations and multiple outcomes measurements. Controlling for important covariates is difficult. Because the clinicians already had regulated the 6-MP dose according to the patients’ health state including an ANC, the neutropenic effects of 6-MP might be obscured.
In future studies, a personalized 6-MP dosing plan will be applied in consideration of pharmacokinetics. It is also necessary to validate the effect of NUDT15, TPMT, APEX1, and ITPA genetic variations on 6-MP dosing of pediatric ALL through large-scale studies. These studies would help clarify new candidates and increase the number of patients who can benefit from the various pharmacogenetic markers.
Supplementary Materials
The following are available online at
Author Contributions
Conceptualization, J.M.L., Y.J.S. and J.-S.H.; methodology and investigation, J.M.L. and J.-S.H.; formal analysis, J.M.L., Y.J.S. and J.-S.H.; data curation J.M.L., D.-H.K., N.J. and Y.J.S.; writing—original draft preparation, J.M.L., Y.J.S., D.-H.K., N.J. and J.-S.H.; writing—review and editing, J.M.L., Y.J.S. and J.-S.H.; supervision, J.-S.H. All authors have read and agreed to the published version of the manuscript.
Funding
This work was supported by the research promoting grant from the Institute for Cancer Research Keimyung University Dongsan Medical Center in 2019.
Institutional Review Board Statement
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Yeungnam University Hospital (YUMC 2019-12-007) and Keiymung University Dongsan Hospital (2019-11-074).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
The data presented in this study are available on request from the corresponding author.
Acknowledgments
We thank K.S.P., K.S.L., T.Y.P. and S.H.W. for good assistance with sample collection, DNA extraction and sequencing analysis.
Conflicts of Interest
The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures and Tables
Enlarge this image.Figure 1. Genotype of NUDT15 c.415C>A and adjusted 6-MP dose at second, sixth, and final maintenance periods. The adjusted 6-MP dose at final maintenance period was significantly low in patients carrying CA heterozygote than those with wild CC genotype.
Enlarge this image.Figure 2. Genotype of NUDT15 c.415C>A and 6-MP dose intensity (%) at second, sixth, and final maintenance periods. The 6-MP intensity was significantly low in patients carrying CA heterozygote than those with wild genotype at sixth and final maintenance therapy periods.
Characteristics and genotype frequencies of pediatric acute lymphoblastic leukemia patients enrolled in this study.
| Characteristics | |
|---|---|
| Total number of patients, n (%) | 83 |
| Sex, n (%) | |
| Female | 27 (32.5) |
| Male | 56 (67.5) |
| Risk group, n (%) | |
| Standard risk | 52 (62.7) |
| High risk | 25 (30.1) |
| Very high risk | 6 (7.2) |
| Age at diagnosis, median (range) | 8.3 (1.0–16.2) |
| Leukemia type, n (%) | |
| B-ALL | 68 (81.9) |
| T-ALL | 8 (9.6) |
| Mixed-type | 4 (4.8) |
| Unclassified | 3 (3.6) |
| Cytogenetic abnormality, n (%) | |
| Normal | 28 (33.7) |
| Hyperdiploidy | 13 (15.7) |
| t(12;21)(p13;q22); ETV6-RUNX1 | 12 (14.5) |
| t(4;11)(q21;q23); MLL-AFF1 | 3 (3.6) |
| t(1;19)(q23;p13.3); TCF3-PBX1 | 3 (3.6) |
| t(9;22)(q34;q11.2); BCR-ABL1 | 1 (1.2) |
| Hypodiploidy | 1 (1.2) |
| Other/unknown | 22 (26.5) |
| Neutropenia (mean ± SD) | |
| ANC at 14th day (/mm3) | 708.8 ± 824.1 |
| ANC at 28th day (/mm3) | 188.6 ± 383.4 |
| Days of ANC < 1 × 103/mm3 (n = 76) | 268.3 ± 224.8 |
| Days of ANC < 0.5 × 103/mm3 (n = 70) | 136.8 ± 132.0 |
| Days of febrile neutropenia (n = 61) | 6.1 ± 5.3 |
| 6-MP dose (mg/m2, mean ± SD) | |
| First maintenance | 75 |
| Second maintenance | 51.6 ± 19.1 |
| Sixth maintenance | 48.5 ± 16.5 |
| Final maintenance | 45.3 ± 15.3 |
| 6-MP dose intensity * | |
| Second maintenance | 70.0 ± 24.8 |
| Sixth maintenance | 66.3 ± 22.5 |
| Final maintenance | 61.7 ± 21.0 |
| Maximum AST, (IU, mean ± SD) | 303.9 ± 220.7 |
| Maximum ALT, (IU, mean ± SD) | 636.3 ± 458.6 |
| Genotype, n (%) | |
| NUDT15 55_56insGAGTCG (rs746071566) | |
| Wild | 74 (89.2) |
| 55_56insGAGTCG | 9 (10.8) |
| NUDT15 c.415C>T (rs116855232) | |
| CC | 67 (80.7) |
| CA | 16 (19.3) |
| ITPA c.94C>A (rs1127354) | |
| CC | 62 (74.7) |
| CA | 21 (25.3) |
| ITPA c.IVS2+21A>C (rs7270101) | |
| AA | 82 (98.8) |
| AC | 1 (1.2) |
| APEX1 c.190A>G (rs2307486) | |
| AA | 74 (89.2) |
| AG | 9 (10.8) |
| TPMT | |
| *1/*1 | 82 (98.8) |
| *1/*3 | 1 (1.2) |
| NUDT15 c.415C>T + ITPA c.94C>A | 5 (6.0) |
| NUDT15 c.415C>T + APEX1 c.190A>G | 1 (1.2) |
| TPMT *1/*3 + ITPA c.94C>A | 1 (1.2) |
| ITPA c.94C>A + APEX1 c.190A>G | 2 (2.4) |
* 6-MP dose intensity: ratio of actual prescribed 6-MP dose by physician and the protocol dose. Abbreviations: ANC, absolute neutrophil count; 6-MP, 6-mercaptopurine; NUDT15, nucleoside diphosphate-linked moiety X-type motif 15; ITPA, inosine triphosphate pyrophosphatase; APEX1, apurinic/apyrimidinic endonuclease 1; TPMT, thiopurine S-methyltransferase.
Table 2Relationships between genotypes of candidate genes and parameters for 6-MP-related toxicities and intolerance.
| ITPA rs1127354 | APEX1 rs2307486 | NUDT15 rs116855232 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Charcteristics | Genotype | CC (n = 62) |
p | Genotype | AA (n = 74) |
p | Genotype | CC (n = 67) |
p * |
| 14th day ANC (/mm3) | CC | 1588.2 ± 1175.2 | 0.539 | AA | 1730.8 ± 1577.8 | 0.070 | CC | 1688.1 ± 1627.5 | 0.884 |
| CA | 1850.4 ± 2269.3 | AG | 814.5 ± 740.1 | CT | 1421.5 ± 1087.5 | ||||
| 28th day ANC (/mm3) | CC | 1482.2 ± 1112.5 | 0.379 | AA | 1425.9 ± 1169.3 | 0.677 | CC | 1561.5 ± 1223.8 | 0.095 |
| CA | 1274.4 ± 1246.7 | AG | 1443.8 ± 960.6 | CT | 892.4 ± 478.8 | ||||
| Days of ANC < 1 × 103/mm3 | CC | 260.5 ± 228.3 | 0.540 | AA | 262.4 ± 223.6 | 0.451 | CC | 263.9 ± 224.8 | 0.564 |
| CA | 290.1 ± 218.3 | AG | 321.6 ± 244.0 | CT | 285.9 ± 231.2 | ||||
| Days of ANC < 0.5 × 103/mm3 | CC | 127.3 ± 130.9 | 0.317 | AA | 131.6 ± 128.2 | 0.377 | CC | 133.9 ± 130.2 | 0.527 |
| CA | 163.2 ± 134.6 | AG | 182.8 ± 165.1 | CT | 148.3 ± 142.7 | ||||
| Days of febrile neutropenia | CC | 6.00 ± 5.56 | 0.608 | AA | 5.9 ± 5.3 | 0.383 | CC | 5.7 ± 5.1 | 0.102 |
| CA | 6.52 ± 4.70 | AG | 7.5 ± 5.1 | CT | 7.5 ± 6.0 | ||||
| 6-MP dose at second maintenance period (mg/m2) | CC | 50.5 ± 7.45 | 0.319 | AA | 51.4 ± 19.1 | 0.837 | CC | 53.0 ± 19.5 | 0.814 |
| CA | 54.6 ± 19.0 | AG | 52.8 ± 19.3 | CT | 45.6 ± 15.9 | ||||
| 6-MP dose at sixth maintenance period (mg/m2) | CC | 48.3 ± 16.7 | 1.000 | AA | 47.9 ± 17.1 | 0.615 | CC | 51.0 ± 15.6 | 0.123 |
| CA | 48.8 ± 16.4 | AG | 54.1 ± 6.7 | CT | 38.1 ± 16.3 | ||||
| 6-MP dose at final maintenance treatment (mg/m2) | CC | 45.6 ± 15.5 | 0.912 | AA | 45.0 ± 15.8 | 0.928 | CC | 47.7 ± 13.8 | 0.007 |
| CA | 44.5 ± 14.9 | AG | 47.7 ± 8.8 | CT | 35.4 ± 17.6 | ||||
| 6-MP dose intensity † at second maintenance period (%) | CC | 68.1 ± 25.6 | 0.235 | AA | 67.0 ± 24.8 | 0.877 | CC | 72.7 ± 24.3 | 0.127 |
| CA | 75.2 ± 21.9 | AG | 70.4 ± 25.8 | CT | 59.2 ± 24.2 | ||||
| 6-MP dose intensity † at sixth maintenance period (%) | CC | 65.5 ± 23.1 | 0.788 | AA | 65.6 ± 23.3 | 0.797 | CC | 70.6 ± 20.1 | 0.003 |
| CA | 68.2 ± 21.0 | AG | 72.1 ± 9.0 | CT | 49.4 ± 23.6 | ||||
| 6-MP dose intensity † at final maintenance period (%) | CC | 61.6 ± 21.8 | 0.792 | AA | 61.5 ± 21.7 | 0.866 | CC | 65.9 ± 17.8 | 0.008 |
| CA | 61.8 ± 18.7 | AG | 63.6 ± 11.7 | CT | 45.5 ± 24.5 | ||||
| Maximum AST | CC | 298.3 ± 210.6 | 0.883 | AA | 305.7 ± 227.5 | 0.785 | CC | 308.1 ± 218.0 | 0.727 |
| CA | 646.6 ± 485.1 | AG | 286.8 ± 154.6 | CT | 286.6 ± 237.5 | ||||
| Maximum ALT | CC | 646.7 ± 485.1 | 0.974 | AA | 655.0 ± 474.0 | 0.255 | CC | 658.0 ± 478.4 | 0.427 |
| CA | 606.9 ± 383.6 | AG | 467.3 ± 240.9 | CT | 549.1 ± 369.1 | ||||
* p < 0.05 was considered statistically significant. † 6-MP dose intensity: the ratio of actual prescribed 6-MP dose by physician and the protocol dose. Abbreviations: ANC, absolute neutrophil count; 6-MP, 6-mercaptopurine; NUDT15, nucleoside diphosphate-linked moiety X-type motif 15; ITPA, inosine triphosphate pyrophosphatase; APEX1, apurinic/apyrimidinic endonuclease 1.
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Ye Jee Shim 2 ; Do-Hoon, Kim 3 ; Jung, Nani 2 ; Jung-Sook Ha 3 1 Department of Pediatrics, Yeungnam University College of Medicine, Daegu 42415, Korea;
2 Department of Pediatrics, Keimyung University School of Medicine, Daegu 42601, Korea;
3 Department of Laboratory Medicine, Keimyung University School of Medicine, Daegu 42601, Korea;